What are Aquestive Therapeutics, Inc.'s total assets?

Aquestive Therapeutics, Inc. (AQST) holds $141.1M in total assets, up 38.0% year over year.

How much debt does Aquestive Therapeutics, Inc. have?

Aquestive Therapeutics, Inc. carries $64.4M in total debt against -$34.1M of shareholders' equity, a debt-to-equity ratio of -1.89.

How much cash does Aquestive Therapeutics, Inc. have?

Aquestive Therapeutics, Inc. holds $110.7M in cash and equivalents.

Can Aquestive Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 4.10 — current assets exceed current liabilities.

Where does Aquestive Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Aquestive Therapeutics, Inc. AQST Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$110.73M+61.3%	$121.17M+69.4%	$129.06M+65.7%	$60.54M-32.6%	$68.66M-27.9%
Inventories	$8.07M+12.1%	$6.17M+2.1%	$7.88M+12.3%	$8.13M+16.6%	$7.2M-6.9%
Raw materials	$4.32M+45.7%	$3.14M-3.8%	$3.68M+13.5%	$4.17M+34.9%	$2.96M-2.6%
Finished goods	$1.23M-35.2%	$664K+3.3%	$1.42M+35.1%	$1.29M-9.5%	$1.89M+4.0%
Prepaid expenses and other current assets	$4.52M+57.4%	$4.17M+26.8%	$2.93M+48.3%	$1.2M+1.6%	$2.87M+35.3%
Total current assets	$130.18M+46.0%	$149.27M+69.2%	$151.67M+57.1%	$81.72M-21.4%	$89.17M-21.4%
Property and equipment, net	$3.84M+1.0%	$3.89M+2.5%	$3.92M+1.8%	$3.86M-1.6%	$3.8M-6.1%
Accumulated depreciation	$44.13M+1.1%	$44.02M+1.2%	$43.9M+1.2%	$43.77M+1.3%	$43.63M+1.4%
Operating lease right-of-use assets	$4.47M-11.5%	$4.62M-10.8%	$4.77M-10.2%	$4.91M-9.6%	$5.05M-7.2%
Deferred tax assets	——	$2.97M-56.8%	——	——	——
Other non-current assets	$635K-47.7%	$642K-47.5%	$1.2M-2.5%	$1.21M-2.4%	$1.22M-14.3%
Allowance for credit losses	——	$178K-4.3%	——	——	——
Total assets	$141.13M+38.0%	$160.43M+58.2%	$163.56M+48.7%	$93.7M-20.3%	$102.23M-21.1%
Accounts payable	$11.89M-3.2%	$29.86M+190%	$10.87M+43.5%	$11.95M+110%	$12.28M+16.7%
Accrued expenses	$2.07M-5.5%	$3.71M-21.7%	$3.69M+6.9%	$3.53M+32.3%	$2.19M+26.5%
Deferred revenue	$1.09M+4.2%	$1.09M+4.2%	$1.09M+4.2%	$1.09M+4.4%	$1.05M-32.4%
Current portion of long-term debt	$14.54M+52.4%	$9.54M—	$9.54M—	$9.54M—	$9.54M—
Operating lease liabilities, current	$662K+22.6%	$631K+23.7%	$601K+24.7%	$570K+25.3%	$540K+30.4%
Contract liabilities	$19.12M-3.2%	$19.39M-3.1%	$19.66M-3.0%	$19.94M-8.4%	$19.74M-38.2%
Income taxes payable	$408K-2.2%	$349K-4.4%	$410K-13.3%	$336K-12.0%	$417K-3.7%
Accrued interest	$17K0.0%	$17K0.0%	$17K0.0%	$17K-98.9%	$17K-98.9%
Total current liabilities	$31.75M+73.5%	$47.61M+152%	$25.57M+68.8%	$23.16M+66.6%	$18.3M+1.3%
Deferred tax liabilities	——	$1.75M+120%	——	——	——
Long-term debt	$45M0.0%	$45M0.0%	$45M0.0%	$45M0.0%	$45M0.0%
Operating lease liabilities, non-current	$4.16M-13.7%	$4.34M-12.7%	$4.51M-11.8%	$4.67M-10.9%	$4.82M-8.7%
Operating Lease Liabilities (Total)	$4.82M-10.1%	$4.97M-9.3%	$5.11M-8.6%	$5.24M-8.0%	$5.36M-5.9%
Finance lease liabilities	——	$113K-22.6%	——	——	——
Asset retirement obligations	$2.07M+1.3%	$2.07M+1.3%	——	——	$2.05M—
Other non-current liabilities	$6.05M+173%	$7.27M+204%	$2.06M+1.2%	$2.05M+1.2%	$2.22M+9.7%
Total liabilities	$175.18M+7.4%	$194.09M+20.1%	$167.67M+7.9%	$166.29M+8.6%	$163.16M-1.6%
Common stock	250M0.0%	250M0.0%	250M0.0%	250M0.0%	250M0.0%
Additional paid-in capital	$420.88M+29.5%	$413.21M+36.4%	$410.91M+36.7%	$327M+9.3%	$325.12M+10.0%
Retained earnings	-$455.06M-17.8%	-$447M-23.1%	-$415.14M-19.9%	-$399.69M-19.4%	-$386.14M-16.3%
Total stockholders' equity	-$34.05M+44.1%	-$33.66M+44.0%	-$4.11M+91.0%	-$72.59M-105%	-$60.93M-67.8%
Total liabilities and stockholders' equity	$141.13M+38.0%	$160.43M+58.2%	$163.56M+48.7%	$93.7M-20.3%	$102.23M-21.1%
Contract Assets, Net	——	$435K+29.1%	——	——	——
Other Inventory, Net	——	$435K+29.1%	——	——	——
Other Receivables, Gross	$1.61M—	$9.75M+294%	——	——	——
Capitalized Contract Costs, Net	$442K-6.4%	$449K-6.5%	$457K-6.4%	$465K-6.3%	$472K-32.7%
Deferred Tax Assets and Other Non-Current Assets	$2.64M-37.5%	$4.72M+3,203%	$3.2M-24.4%	$3.21M-24.3%	$4.22M-22.2%
Deferred Tax Assets - Tax Credit Carryforwards	——	$7.53M+47.6%	——	——	——
Net Investment in Lease	$4.47M-11.5%	$4.62M-10.8%	$4.77M-10.2%	$4.91M-9.6%	$5.05M-7.2%
Net Operating Loss Carryforwards	——	$7.53M+47.6%	——	——	——
Operating lease right-of-use assets	$4.47M-11.5%	$4.62M-10.8%	$4.77M-10.2%	$4.91M-9.6%	$5.05M-7.2%
Other non-current assets	$2.64M-37.5%	$2.64M-37.4%	$3.2M-24.4%	$3.21M-24.3%	$4.22M-22.2%
Property, plant and equipment at cost	$47.97M+1.1%	$47.91M+1.3%	$47.82M+1.3%	$47.63M+1.1%	$47.44M+0.7%
Operating Lease Right-of-Use Assets in Other Assets	$4.47M-11.5%	$4.62M-10.8%	$4.77M-10.2%	$4.91M-9.6%	$5.05M-7.2%
Software and Technology Licenses, Net	$2.64M-37.5%	$2.64M-37.4%	$3.2M-24.4%	$3.21M-24.3%	$4.22M-22.2%
Tax Credit Carryforward Valuation Allowance	——	$113.17M+19.7%	——	——	——
Accrued Manufacturing Costs	$2.07M-5.5%	$3.71M-21.7%	$3.69M+6.9%	$3.53M+32.3%	$2.19M+26.5%
Accrued Progress Collections and Price Adjustments	$19.12M-3.2%	$19.39M-3.1%	$19.66M-3.0%	$19.94M-8.4%	$19.74M-38.2%
Other Commercial Liabilities	$3.45M+4.1%	$5.03M-14.9%	$5.13M+2.0%	$5M-11.9%	$3.31M-28.5%
Accrued Liabilities, Current	$3.45M+4.1%	$5.03M-14.9%	$5.13M+2.0%	$5M-11.9%	$3.31M-28.5%
Compensation and benefits	$2.07M-5.5%	$3.71M-21.7%	$3.69M+6.9%	$3.53M+32.3%	$2.19M+26.5%
Current portion of mortgage and loans payable	$13.66M+50,496%	$9.99M+38,338%	$6.33M+25,208%	$3.18M+13,138%	$27K+17.4%
Liability related to the sale of future revenue, current	$1M—	$1M0.0%	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	$991K+2.6%	——	$327K+3.2%	$647K+2.9%	$966K+4.3%
Operating Lease Liability Payments - 2024 (Lessee)	$1.18M-12.3%	$1.35M+2.1%	$1.35M+2.1%	$1.35M+2.1%	$1.35M+3.5%
Operating Lease Liability Payments - 2025 (Lessee)	$1.18M-12.3%	$1M-15.3%	$1.35M+2.1%	$1.35M+2.1%	$1.35M+3.5%
Lease Liability Payments - Due Year Two	$1.18M-12.3%	$1.35M+2.1%	$1.35M+2.1%	$1.35M+2.1%	$1.35M+3.5%
Lease Liability Payments - Due Year Three	$1M-15.3%	$1.18M-12.3%	$1.18M-12.3%	$1.18M-12.3%	$1.18M-11.1%
Lease Liability Payments - Remainder of Fiscal Year	$1.35M+2.1%	$1.32M+2.6%	$1.32M+2.6%	$1.32M+2.6%	$1.32M+4.1%
Operating Lease Liability Payments Due	$7.43M-14.8%	$7.76M-14.2%	$8.09M-13.6%	$8.41M-13.1%	$8.73M-11.1%
Operating Lease Liability - Undiscounted Excess Amount	$2.61M-22.4%	$2.79M-21.7%	$2.98M-21.0%	$3.17M-20.4%	$3.36M-18.2%
Contract Liabilities, Non-Current	$19.12M-3.2%	$19.39M-3.1%	$19.66M-3.0%	$19.94M-8.4%	$19.74M-38.2%
Debt Maturity - 2024	$9.54M—	——	$0—	$0—	$0—
Debt Maturity - 2027	$20.93M0.0%	$20.93M+44.0%	$20.93M+44.0%	$20.93M+44.0%	$20.93M+44.0%
Operating Lease Liability Payments - 2027 (Lessee)	$1M-15.3%	$2.92M-25.5%	$1.18M-12.3%	$1.18M-12.3%	$1.18M-11.1%
Long-Term Debt and Finance Lease Obligations	$25.1M—	$27.52M-15.3%	——	——	——
Deferred revenue, net of current portion	$19.12M-3.2%	$19.39M-3.1%	$19.66M-3.0%	$19.94M-8.4%	$19.74M-38.2%
Total debt	$64.36M+7.4%	$59.62M+17.8%	$59.65M+17.9%	$59.78M+17.9%	$59.9M+18.2%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	124.3M+25.1%	122M+33.5%	121.7M+33.4%	99.4M+9.1%	99.3M+9.8%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$124K+25.3%	$122K+34.1%	$121K+33.0%	$99K+8.8%	$99K+10.0%
Shares Reserved for Future Issuance Under Stock Plans	——	307.8K-84.6%	——	——	——
Warrants and Rights Outstanding	375K—	——	——	——	——
Cumulative Cost Basis	$47.97M+1.1%	$47.91M+1.3%	$47.82M+1.3%	$47.63M+1.1%	$47.44M+0.7%
Accounts Receivable, Allowance for Credit Loss, Pre-Reclassification	$0—	$582K+1,113%	——	——	——
Accounts Receivable Allowances and Accruals - Trade and Other Receivables, Net	$0—	$582K—	——	——	——
Asset Retirement Obligation	$2.07M+1.3%	$2.07M+1.3%	——	——	$2.05M—
Capitalized Contract Cost, Net	$442K-6.4%	$449K-6.5%	$457K-6.4%	$465K-6.3%	$472K-32.7%
Common stock, capital shares reserved for future issuance	——	$307.85K—	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$250M0.0%	$250M0.0%	$250M0.0%	$250M0.0%	$250M0.0%
Common stock, shares issued (in shares)	$124.28M+25.1%	$122.04M+33.5%	$121.66M+33.4%	$99.35M+9.1%	$99.32M+9.8%
Common Stock, Shares, Outstanding	$124.28M+25.1%	$122.04M+33.5%	$121.66M+33.4%	$99.35M+9.1%	$99.32M+9.8%
Contract with Customer, Asset, after Allowance for Credit Loss	$445K-38.0%	$627K+8.5%	$678K+3.7%	$645K+7.3%	$718K+2.6%
Contract with Customer, Liability	$20.21M-2.8%	$20.48M-2.7%	$20.76M-2.6%	$21.03M-7.8%	$20.79M-37.9%
Royalty receivable	$2M-33.3%	$2M-33.3%	$2M-33.3%	$2M-33.3%	$3M-25.0%
Deferred Tax Liabilities, Gross	——	$1.75M+120%	——	——	——
Sales of Royalty Rights	——	$5.06M+47.0%	——	——	——
Deferred Tax Assets, Goodwill and Intangible Assets	——	$1.21M+785%	——	——	——
Deferred Tax Assets, Gross	——	$114.92M+20.5%	——	——	——
Deferred Tax Assets, Net of Valuation Allowance	——	$0—	——	——	——
OID and Deferred Financing Cost	——	$2M+22.5%	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards	——	$48.76M+40.6%	——	——	——
Fixed assets	——	$2.32M-13.6%	——	——	——
Royalty Monetization	——	$16.29M+1.1%	——	——	——
R&D credit carryforward	——	$6.91M-4.9%	——	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	——	$2.97M-56.8%	——	——	——
Temporary differences related to Texas Margin Tax	——	$178K-4.3%	——	——	——
Deferred Tax Assets, Valuation Allowance	——	$113.17M+19.7%	——	——	——
Prepaid expenses	——	$586K-26.3%	——	——	——
Deferred Tax Liabilities, Right Of Use Assets	——	$1.16M—	——	——	——
Employee retention tax credit, refund	——	$1.4M—	——	——	——
Packaging material	$2.52M+7.6%	$2.36M+10.6%	$2.79M+2.1%	$2.67M+8.8%	$2.34M-18.4%
Raw materials	$4.32M+45.7%	$3.14M-3.8%	$3.68M+13.5%	$4.17M+34.9%	$2.96M-2.6%
Lessee Operating Lease Liability Payments Due	$7.43M-14.8%	$7.76M-14.2%	$8.09M-13.6%	$8.41M-13.1%	$8.73M-11.1%
2030 and thereafter	$2.92M-25.5%	——	$3.92M-23.2%	$3.92M-23.1%	$3.92M-21.5%
Lessee Operating Lease Liability Undiscounted Excess Amount	$2.61M-22.4%	$2.79M-21.7%	$2.98M-21.0%	$3.17M-20.4%	$3.36M-18.2%
Liabilities, Sale of Future Royalties	$63.08M-1.1%	$63.02M-1.1%	$62.98M-1.2%	$62.92M-1.2%	$63.78M-1.2%
Liability related to the sale of future revenue, current	$1M0.0%	$1M0.0%	$1M0.0%	$1M0.0%	$1M+9.9%
Long-Term Debt and Lease Obligation	$25.1M—	$27.52M-15.3%	——	——	——
2028	$20.93M+44.0%	$14.54M+52.4%	$14.54M+52.4%	$14.54M+52.4%	$14.54M+52.4%
2027	$14.54M+52.4%	$9.54M—	$9.54M—	$9.54M—	$9.54M—
Remainder of 2026	$9.54M—	——	$0—	$0—	$0—
Number of leases	30.0%	——	30.0%	30.0%	30.0%
Other accrued liabilities	$53K-35.4%	$50K-60.9%	$83K-81.1%	$112K-74.3%	$82K-72.4%
Royalty obligations, net	$26.91M+24.8%	$25.94M+28.9%	$23.95M—	$22.71M—	$21.56M—
Royalty Obligations, Gross	——	$51.89M-8.8%	——	——	——
Royalty Obligations, Net	——	$25.94M+28.9%	——	——	——
Severance liability	——	——	——	——	——
Incentive stock program, shares reserved for future grants (in shares)	——	$4M+100%	——	——	——
Interest limitation imposed by the TCJA	——	$11.39M-1.7%	——	——	——
Liability related to the sale of future revenue, net	$62.08M-1.1%	$62.02M-1.1%	$61.98M-1.2%	$61.92M-1.2%	$62.78M-1.3%
Warrants And Rights Outstanding	$916K—	——	——	——	——
Remainder of Fiscal Year 2024	$9.54M—	——	$0—	$0—	$0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Aquestive Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Aquestive Therapeutics, Inc.'s total assets?: Aquestive Therapeutics, Inc. (AQST) holds $141.1M in total assets, up 38.0% year over year.
How much debt does Aquestive Therapeutics, Inc. have?: Aquestive Therapeutics, Inc. carries $64.4M in total debt against -$34.1M of shareholders' equity, a debt-to-equity ratio of -1.89.
How much cash does Aquestive Therapeutics, Inc. have?: Aquestive Therapeutics, Inc. holds $110.7M in cash and equivalents.
Can Aquestive Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 4.10 — current assets exceed current liabilities.
Where does Aquestive Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.